EMA lists paediatric priorities for off-patent drugs as new EC funding nears
This article was originally published in Scrip
Following a two-year drought, the European Commission's seventh framework programme (FP7) is to make fresh funding available next year for companies wishing to develop paediatric forms of off-patent drugs.
You may also be interested in...
The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.
Health ministers have called for more action on access to medicines, including a new EU work agenda, rebuilding Europe’s manufacturing capabilities, further action on pricing, and greater leeway for member states to mitigate drug shortages by restricting parallel exports.